Breaking News Instant updates and real-time market news.

MTNB

Matinas BioPharma

$1.14 /

-0.02 (-1.73%)

07:32
10/21/21
10/21
07:32
10/21/21
07:32

Matinas BioPharma initiates dosing in Phase 1 study of MAT2501

Matinas BioPharma Holdings announced that it has dosed the first patient in a Phase 1 single ascending dose pharmacokinetic study in healthy volunteers with MAT2501. The Company expects to complete enrollment of the Phase 1 SAD study in the first quarter of 2022, with data anticipated during the second quarter of 2022. Pending successful completion of the Phase 1 SAD study, the Company expects to start a Phase 2 program in patients with nontuberculous mycobacterial infections by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022. MAT2501 is being developed to potentially become the first oral aminoglycoside, with the application of Matinas' proprietary LNC platform technology to the broad-spectrum antibiotic drug amikacin. Amikacin is a highly potent antibiotic used to treat chronic and acute bacterial infections, including problematic gram-negative infections. Currently, amikacin's use is severely limited due to associated major side effects including nephrotoxicity and ototoxicity, as well as inhalation complications with certain approved therapies. This Phase 1 study is a double-blind, placebo-controlled, SAD study designed primarily to evaluate the safety, tolerability and pharmacokinetics of single ascending oral doses of MAT2501 in healthy adult subjects. Secondary objectives include the assessment of the effect of food on the pharmacokinetics of amikacin following a single oral dose of MAT2501. Development of MAT2501 has been supported by a $4.2 million Therapeutics Development Award from the Cystic Fibrosis Foundation. The U.S. Food and Drug Administration has designated MAT2501 as a Qualified Infectious Disease Product and as an Orphan Drug for the treatment of NTM. If MAT2501 is ultimately approved by the FDA, the seven-year period of marketing exclusivity from orphan designation combined with the additional five years of marketing exclusivity provided by the QIDP designation, would provide for a potential total of 12 years of marketing exclusivity.

  • 01

    Nov

MTNB Matinas BioPharma
$1.14 /

-0.02 (-1.73%)

09/13/21 Piper Sandler
Matinas' next steps for MAT2203 'still unclear,' says Piper Sandler
05/11/21 Piper Sandler
Matinas BioPharma downgraded to Neutral from Overweight at Piper Sandler
03/30/21 H.C. Wainwright
Matinas BioPharma price target lowered to $3 from $4 at H.C. Wainwright
02/01/21 Piper Sandler
Matinas trial shows 'robust' serum increass despite miss, says Piper Sandler

TODAY'S FREE FLY STORIES

General news
Fed's Bostic played down risks from the new Omicron variant » 17:40
11/26/21
11/26
17:40
11/26/21
17:40
$ECON

Economic Data

/

+

Fed's Bostic played…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Treasury Market Summary » 17:30
11/26/21
11/26
17:30
11/26/21
17:30
$ECON

Economic Data

/

+

Treasury Market Summary:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet reserve bank credit $24.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet total assets $6.8B  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

General news
Week of 11/24 Fed balance sheet level $8.682T  16:34
11/26/21
11/26
16:34
11/26/21
16:34
$ECON

Economic Data

/

+

 
ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Technical Analysis
NASDAQ market internals summary » 16:23
11/26/21
11/26
16:23
11/26/21
16:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 16:22
11/26/21
11/26
16:22
11/26/21
16:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 346,472,000 / Declining Volume: 3,140,522,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:13
11/26/21
11/26
16:13
11/26/21
16:13
SNOW

Snowflake

$361.94 /

+6.655 (+1.87%)

, CRWD

Crowdstrike

$233.73 /

+2.93 (+1.27%)

, SPLK

Splunk

$125.25 /

+0.2 (+0.16%)

, VEEV

Veeva

$288.19 /

-2.64 (-0.91%)

Technology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

11/19/21
Fly Intel: Top five analyst downgrades
11/19/21 Rosenblatt
Snowflake downgraded to Neutral on valuation at Rosenblatt
11/19/21 Rosenblatt
Snowflake downgraded to Neutral from Buy at Rosenblatt
11/16/21 Credit Suisse
Snowflake initiated with an Outperform at Credit Suisse
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

11/24/21 Deutsche Bank
Crowdstrike price target lowered to $300 from $320 at Deutsche Bank
11/18/21
Fly Intel: Top five analyst initiations
11/18/21 DA Davidson
Crowdstrike initiated with a Buy at DA Davidson
11/15/21
Fly Intel: Top five analyst initiations
SPLK Splunk
$125.25 /

+0.2 (+0.16%)

11/17/21 Argus
Argus 'surprised' by Splunk's 'abrupt' CEO dismissal
11/16/21 Mizuho
Splunk price target lowered to $165 from $175 at Mizuho
11/16/21 Credit Suisse
Splunk initiated with an Outperform at Credit Suisse
11/16/21 Deutsche Bank
Splunk price target lowered to $155 from $180 at Deutsche Bank
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

10/01/21 Stifel
Veeva assumed with a Buy at Stifel
09/03/21 SVB Leerink
Veeva price target raised to $296 from $294 at SVB Leerink
09/02/21 UBS
Veeva price target raised to $320 from $270 at UBS
09/02/21 Baird
Veeva price target raised to $349 from $340 at Baird
VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

  • 16
    Mar
CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

VEEV Veeva
$288.19 /

-2.64 (-0.91%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

SPLK Splunk
$125.25 /

+0.2 (+0.16%)

SNOW Snowflake
$361.94 /

+6.655 (+1.87%)

CRWD Crowdstrike
$233.73 /

+2.93 (+1.27%)

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 16:08
11/26/21
11/26
16:08
11/26/21
16:08
CRM

Salesforce

$283.00 /

-6.155 (-2.13%)

, ZS

Zscaler

$337.00 /

-5.25 (-1.53%)

Technology Analysts…

Technology Analysts provide a recap of salesforce.com and Zscaler reported earnings on an Analyst/Industry conference call to be held on December 1 at 8:30 am.

ShowHide Related Items >><<
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

11/23/21 BofA
Salesforce price target raised to $360 from $330 at BofA
11/23/21 Jefferies
Salesforce price target raised to $360 from $325 at Jefferies
11/23/21 Citi
Salesforce price target raised to $308 from $280 at Citi
11/22/21 Atlantic Equities
Atlantic Equities assumes 'low-risk' Salesforce at Overweight
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

11/24/21 Deutsche Bank
Zscaler price target raised to $400 from $325 at Deutsche Bank
11/16/21 Credit Suisse
Zscaler initiated with an Outperform at Credit Suisse
11/15/21 Mizuho
Zscaler price target raised to $385 from $320 at Mizuho
11/09/21 BTIG
Zscaler price target raised to $401 from $324 at BTIG
ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

ZS Zscaler
$337.00 /

-5.25 (-1.53%)

CRM Salesforce
$283.00 /

-6.155 (-2.13%)

Hot Stocks
Moderna testing existing and new variant-specific vaccine candidates for Omicron » 15:37
11/26/21
11/26
15:37
11/26/21
15:37
MRNA

Moderna

$331.10 /

+57.83 (+21.16%)

Moderna announced updates…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

12:35 Today Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

MRNA Moderna
$331.10 /

+57.83 (+21.16%)

Conference/Events
UBS biotechnology analysts to hold an analyst/industry conference call » 15:29
11/26/21
11/26
15:29
11/26/21
15:29

Biotech Analysts Merle…

Biotech Analysts Merle & Rajavelu provide perspectives on the upcoming Phase 3 Data readouts for ATTR-CM (Transthyretin Amyloid Cardiomyopathy) data readouts on an Analyst/Industry conference call to be held on November 30 at 10 am.

Technical Analysis
NASDAQ market internals summary » 15:23
11/26/21
11/26
15:23
11/26/21
15:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 15:22
11/26/21
11/26
15:22
11/26/21
15:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 469 / Declining Issues: 2860 -- for a ratio of 0.2 to 1. Advancing Volume: 344,464,000 / Declining Volume: 3,113,466,000 -- for a ratio of 0.1 to 1. New 52-Week Highs: 21 / New 52-Week Lows: 210.

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
UBS technology analysts to hold an analyst/industry conference call » 15:20
11/26/21
11/26
15:20
11/26/21
15:20

Technology Analysts…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
UBS restaurants analyst to hold analyst/industry conference call » 15:15
11/26/21
11/26
15:15
11/26/21
15:15

Restaurants Analyst…

Restaurants Analyst Geiger, along with a quick serve restaurant coffee franchisee, discuss the industry on an Analyst/Industry conference call to be held on November 29 at 11 am.

Conference/Events
UBS consumer goods analyst to hold analyst/industry conference call » 15:12
11/26/21
11/26
15:12
11/26/21
15:12

Consumer Goods Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Cowen pharma/biotech analysts to hold an analyst/industry conference call » 15:03
11/26/21
11/26
15:03
11/26/21
15:03

Pharmaceuticals Analyst…

Pharmaceuticals Analyst Scala and Biotech Analyst Rodriguez-Dumont discuss the current status and future opportunities for women's health on an Analyst/Industry conference call to be held on December 3 at 10 am.

Conference/Events
Cowen financial services analyst to hold analyst/industry conference call » 14:59
11/26/21
11/26
14:59
11/26/21
14:59

Head of Equity…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Cowen media & entertainment analyst to hold analyst/industry conference call » 14:54
11/26/21
11/26
14:54
11/26/21
14:54
DISCA

Discovery

$24.72 /

-0.47 (-1.87%)

Media & Entertainment…

Media & Entertainment Analyst Creutz and TMT Policy Analyst Gallant discusses the Discovery-Time Warner merger-spin including the fundamental value, regulatory risk and when-issued market on an Analyst/Industry conference call to be held on December 2 at 11 am.

ShowHide Related Items >><<
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

11/08/21 Macquarie
Macquarie upgrades Discovery to Outperform, raises target to $40
11/08/21 Macquarie
Discovery upgraded to Outperform from Neutral at Macquarie
11/01/21 Bernstein
Bernstein upgrades Discovery to Market Perform, lowers target to $26
11/01/21 Bernstein
Discovery upgraded to Market Perform from Underperform at Bernstein
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

  • 14
    Apr
DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

DISCA Discovery
$24.72 /

-0.47 (-1.87%)

Conference/Events
Cowen ESG & restaurant analysts hold analyst/industry conference call » 14:47
11/26/21
11/26
14:47
11/26/21
14:47

ESG Policy Analyst Miller…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
FX Action: USD-JPY » 14:40
11/26/21
11/26
14:40
11/26/21
14:40
$ECON

Economic Data

/

+

FX Action: USD-JPY…

FX Action: USD-JPY revealed its safe-haven credentials, falling to near three-week lows of 113.05 on the back of the new Covid variant, and the slide in Treasury yields. The pairing had topped at 115.34 overnight. With answers on the new variant likely to take a couple of weeks, the yen may remain in favor for now.

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Conference/Events
Cowen surface transport/logistics analyst holds analyst/industry conference call » 14:26
11/26/21
11/26
14:26
11/26/21
14:26

Surface…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Technical Analysis
NASDAQ market internals summary » 14:23
11/26/21
11/26
14:23
11/26/21
14:23
$NSD

NASDAQ Market Internals

/

+

Volume is above average…

Volume is above average for this time of day. Breadth is bearish across the board. Advancing Issues: 919 / Declining Issues: 3632 -- for a ratio of 0.3 to 1. Advancing Volume: 996,010,000 / Declining Volume: 2,412,588,000 -- for a ratio of 0.4 to 1. New 52-Week Highs: 35 / New 52-Week Lows: 349.

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
/

+

Technical Analysis
NYSE market internals summary » 14:22
11/26/21
11/26
14:22
11/26/21
14:22
$NYE

NYSE Market Internals

/

+

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
/

+

Conference/Events
Cowen retail/luxury goods analyst to hold analyst/industry conference call » 14:22
11/26/21
11/26
14:22
11/26/21
14:22

Retail & Luxury Goods…

Retail & Luxury Goods Analyst Chen, along with RetailNext, discuss Black Friday and Cyber Monday on an Analyst/Industry conference call to be held on November 29 at 11 am.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.